Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Anticancer Research|July 3, 2019
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, et al.
Cancer Research|October 14, 2010
Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancerSatoshi Kohmo, Takashi Kijima, Yasushi Otani, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2015
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)Kazumi Nishino, Fumio Imamura, Toru Kumagai, et al.
Clinical Lung Cancer|November 15, 2017
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With NivolumabTakako Inoue, Motohiro Tamiya, Akihiro Tamiya, et al.
Plos One|February 23, 2018
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trialMotohiro Tamiya, Akihiro Tamiya, Takako Inoue, et al.
Oxford Medical Case Reports|June 30, 2022
Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphineKei Kunimasa, Yoshifumi Ohashi, Megumi Okawa, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 28, 2023
Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective studyYukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, et al.
American Journal of Respiratory Cell and Molecular Biology|September 16, 2003
Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growthMasahide Mori, Hiroshi Morishita, Hideji Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2015
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2011
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lungRyo Takahashi, Haruhiko Hirata, Isao Tachibana, et al.
Pageof 13